Phase II Study Treatment of High Risk Non-Hodgkin's Lymphomas
High-dose chemotherapy; untreated aggressive non-Hodgkin's lymphoma; high-risk; peripheral
blood stem cell support Patients were aged from 15 to 60 years
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Complete response
end of treatment
Yes
Noël MILPIED, MDPD
Principal Investigator
Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang GOELAMS
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
GOELAMS 073
NCT00869284
October 1994
February 2009
Name | Location |
---|